A PROMISE FOR A HEALTHIER TOMORROW

NaporespF.C.Tablet

Naporesp
Naporesp
The first and only selective PDE4 inhibitor approved by FDA to decrease the exacerbations or worsening of the symptoms from severe COPD.
Composition:

Each film coated tablet contains: Roflumilast 500 mcg

Propertise:
  • The U.S. Food and Drug Administration (FDA) approved Roflumilast taken daily to decrease the frequency of flare ups (exacerbations) or worsening of symptoms from severe chronic obstructive pulmonary disease (COPD).
  • Roflumilast: is a new drug class for the treatment of COPD, is an inhibitor of an enzyme phosphodiesterase type 4 (PDE-4).
  • Roflumilast: is indicated for people with severe COPD to treat the symptoms of cough and excess mucus linked to bronchitis.
  • Roflumilast: is not intended to treat another form of COPD which involves primary emphysema.
  • The safety and effectiveness of Roflumilast was demonstrated in many clinical studies that show satisfactory results.
Dosage & Administration:

One tablet to be taken orally. Once or twice daily or as directed by the physician.